Showing 1841-1850 of 2034 results for "".
- ProQR Receives Orphan Drug Designation from FDA for QR-1123 for Autosomal Dominant Retinitis Pigmentosahttps://modernod.com/news/proqr-receives-orphan-drug-designation-from-fda-for-qr-1123-for-autosomal-dominant-retinitis-pigmentosa/2477112/ProQR Therapeutics announced that it received orphan drug designation (ODD) from the FDA for QR-1123, a first-in-class investigational antisense oligonucleotide designed to address the underlying cause of vision loss associated with autosomal dominant retinitis pigmentosa (adRP) due to the P23H m
- Ocular Therapeutix Announces Strategic Update and Operational Restructuringhttps://modernod.com/news/ocular-therapeutix-announces-strategic-update-and-operational-restructuring/2477081/Ocular Therapeutix announced an operational restructuring plan that the company says is expected to result in an estimated $11 million in annualized savings through personnel reductions and approximately $14 million in one-time program deferrals. The company estimates that it will record costs as
- SightGlass Vision to Present New Data on its Novel Lenses to Control Nearsightedness in Children at 3rd World Congress of Optometryhttps://modernod.com/news/sightglass-vision-to-present-new-data-on-its-novel-lenses-to-control-nearsightedness-in-children-at-3rd-world-congress-of-optometry/2477040/SightGlass Vision announced that data from three clinical trials overviewing discovery to clinical development of its novel spectacle lenses will be presented for the first time in a scientific forum at the 3rd World Congress of Optometry (WCO19) and Academy 2019 (Academy19), held
- Alcon Contact Lens and Cataract Innovations to Headline Clinical and Educational Program at #Academy19https://modernod.com/news/alcon-contact-lens-and-cataract-innovations-to-headline-clinical-and-educational-program-at-academy19/2477022/Alcon will bring major contact lens and cataract innovations together for the first time at the 2019 American Academy of Optometry (AAO / #Academy19) meeting taking place October 23-27 at the Orange County Convention Center (OCCC) in Orlando, according to a company news release. Innovations like
- Using AI to Screen for Diabetic Eye Disease Feasible in the Real Worldhttps://modernod.com/news/using-ai-to-screen-for-diabetic-eye-disease-feasible-in-the-real-world/2477017/New research shows that an automated, artificial intelligence (AI) screening system accurately detects diabetic retinopathy 95.5 percent of the time. The system doesn’t require the input of an expert ophthalmologist and it can provide a reading in 60 seconds, making real-time screening possible f
- Norlase Enters Ophthalmic Market With Launch of LEAF Ultra-Compact Green Laser Photocoagulatorhttps://modernod.com/news/norlase-enters-ophthalmic-market-with-launch-of-leaf-ultra-compact-green-laser-photocoagulator/2476999/Norlase announced the FDA 510(k) clearance and immediate commercial launch of LEAF, the company’s flagship laser product for the treatment of retina and glaucoma disease. LEAF allows ophthalmologists to perform laser therapy in almost any exam room, with minimal set-up time and physical space req
- Kodiak Sciences Announces Presentation of Durability Data from Clinical Development Program of KSI-301 in Wet AMD, DME, and RVO at AAOhttps://modernod.com/news/kodiak-sciences-announces-presentation-of-durability-data-from-clinical-development-program-of-ksi-301-in-wet-amd-dme-and-rvo-at-aao/2476945/Kodiak Sciences announced that Charles C. Wykoff, MD, PhD, will present first-time results at the annual mneeting of the American Academy of Ophthalmology (AAO) to be held in San Francisco. The Retina Subspecialty Day (
- Nicox Provides Business Update and Upcoming Milestoneshttps://modernod.com/news/nicox-provides-business-update-and-upcoming-milestones/2476887/Nicox SA reported the financial results for Nicox and its subsidiaries for the 6 months ending June 30, 2019 and provided an update on its activities as well as key upcoming milestones. “This is a compelling and potentially transformative time for Nicox, as we make strong progress in our g
- NHS England to Fund Novartis’ Gene Therapy Luxturna for Inherited Retinal Diseasehttps://modernod.com/news/nhs-england-to-fund-novartis-gene-therapy-luxturna-for-inherited-retinal-disease/2476855/NHS England announced Wednesday funding for Novartis’ Luxturna (voretigene neparvovec) after agreeing a deal with the company that will provide access to the gene therapy from January 2020. The one-time treatment gained European Commission approval last year for patients with vision loss du
- Trial of Tele-Ophthalmology System at Regional Health Board in Scotland Shows Promising Resultshttps://modernod.com/news/trial-of-tele-ophthalmology-system-at-regional-health-board-in-scotland-shows-promising-results/2476808/Researchers at the University of Strathclyde and NHS Forth Valley in Scotland have developed a tele-ophthalmology system that, according to recent data, has reduced the need for follow-up appointments and waiting times for treatments in over 50% of cases, according to a